SCHEMBL5880511

SCHEMBL5880511

COCCN(C)c1ncnc2c1CCN(c1nc3cc(OC)c(OC)cc3c(=O)[nH]1)C2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.38
▸ KDM4E B2RXH2 4/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ EHMT2 Q96KQ7 1/20 0.38
▸ EHMT1 Q9H9B1 1/20 0.38
▸ CASP1 P29466 1/20 0.37
▸ HBB P68871 1/20 0.37
▸ LMNA P02545 4/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPK1 P28482 3/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ THRB P10828 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ CYP1A1 P04798 1/20 0.34
▸ CYP1B1 Q16678 1/20 0.34
▸ KDR P35968 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5880593 0.92 MAPT (0.40) MAPTKDM4ETDP1EHMT2EHMT1
SCHEMBL5880448 0.90 EHMT2 (0.40) MAPTKDM4ETDP1EHMT2EHMT1
SCHEMBL6221698 0.82 KMT5A (0.42) MAPTKDM4EEHMT2CASP1HBB
SCHEMBL5880632 0.80 ACHE (0.43) MAPTKDM4ECASP1HBBLMNA
SCHEMBL5880586 0.79 ACHE (0.52) MAPTEHMT2LMNA
SCHEMBL5880524 0.79 ALDH1A1 (0.43) MAPTKDM4ECASP1HBBLMNA
SCHEMBL5880447 0.78 PDE10A (0.52) MAPTKDM4ELMNAMAPK1ALDH1A1
SCHEMBL27511677 0.78 MAPT (0.38) MAPTKDM4ETDP1CASP1HBB
SCHEMBL5880491 0.76 KIT (0.39) MAPTKDM4EEHMT2CASP1HBB
SCHEMBL5880492 0.76 KIT (0.39) MAPTKDM4EEHMT2CASP1HBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900220-B2 Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists SYNTEX (U.S.A.) LLC (US) 2005-05-31 — — US claimed
EP-1363899-B1 QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2005-05-11 — — EP claimed
US-20030069230-A1 Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists SYNTEX (U.S.A.) LLC 2003-04-10 — — US claimed
US-7091200-B2 Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists SYNTEX U.S.A. LLC (US) 2006-08-15 — — US disclosed
US-6900220-B2 Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists SYNTEX (U.S.A.) LLC (US) 2005-05-31 — — US disclosed
US-20050107365-A1 Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists BECKER CYRUS K (US) 2005-05-19 — — US disclosed
EP-1363899-B1 QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2005-05-11 — — EP disclosed
US-20030069230-A1 Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists SYNTEX (U.S.A.) LLC 2003-04-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069230-A1 Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists ADRB1, ADRB2, ADRA2B MAPT 3801/4885KDM4E 3553/4885TDP1 3881/4885
US-20050107365-A1 Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists ADRB1, ADRB2, ADRA2B MAPT 3776/4885KDM4E 3461/4885TDP1 3884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback